Phase 3 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your eye had cataract surgery at least 12 weeks before the first screening visit, and you now have an artificial lens in it.
- You have been diagnosed with abnormal blood vessel growth (called choroidal neovascularization) in your eye caused by age-related macular degeneration (AMD), and the affected area is below a certain size (confirm with trial site).
- You have received at least 2 injections into the eye (anti-VEGF treatment) in the past 6 months, and your doctor considers that your eye has responded to those injections.
Who may not be able to join:
- The abnormal blood vessel growth or swelling in your eye is caused by something other than age-related macular degeneration.
- You were diagnosed with the wet form of AMD more than 4 years before the first screening visit.
- There is a certain type of fluid-filled blister (pigment epithelial detachment) in your eye that is larger than specific size limits, as measured by a specialist reading centre (confirm with trial site).
- There is bleeding under the retina in your eye that covers more than half of the affected area, or that is located in the central part of your vision, as determined by a specialist reading centre.
- There is a tear in a specific layer at the back of your eye (the retinal pigment epithelium) in the central part of your vision, as determined by a specialist reading centre.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Annualized intravitreal anti-VEGF injection rate; Number of Participants Experiencing Adverse Events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.